Brandes Investment Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Brandes Investment Partners’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,500	Closed	-$76K	–	195
2015 Q4	$76K	Hold	2,500	–	–	﹤0.01%	162
2015 Q3	$62K	Sell	2,500 -1,970	-44%	-$58.8K	﹤0.01%	164
2015 Q2	$143K	Hold	4,470	–	–	﹤0.01%	158
2015 Q1	$160K	Buy	+4,470	New	+$123K	﹤0.01%	149
2014 Q3	–	Sell	-1,500	Closed	-$54K	–	169
2014 Q2	$54K	Hold	1,500	–	–	﹤0.01%	158
2014 Q1	$58K	Buy	+1,500	New	+$53.5K	﹤0.01%	165

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Brandes Investment Partners's RIGL Position: Q1 2016 in Review

Brandes Investment Partners sold out of Rigel Pharmaceuticals (RIGL) in Q1 2016, closing a stake of 2,500 shares — an estimated $76K sold.

Brandes Investment Partners first reported a position in RIGL in Q1 2014 and held it in 6 quarters. The position peaked at $160K in Q1 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q1 2016.

Brandes Investment Partners reported no remaining Rigel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Brandes Investment Partners sold 2,500 Rigel Pharmaceuticals shares in Q1 2016, an estimated $76K.
Brandes Investment Partners first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Brandes Investment Partners's Rigel Pharmaceuticals position peaked at $160K in Q1 2015.
120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2016.

Based on Brandes Investment Partners's 13F filing for Q1 2016, filed 12 May 2016.